Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Over 18 Months.

NCT05531656 is registered in ClinicalTrials.gov with Cognition Therapeutics as lead sponsor.

NCT NCT05531656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05531656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Over 18 Months.
Lead sponsor
Cognition Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 28, 2023
Completion date
May 31, 2027
Enrollment
540 (estimated)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

early alzheimer's disease